Genomics PLC Appoints Sekar Kathiresan As Scientific Advisory Board Chair

Genomics plc ("Genomics"), a leading analysis company developing algorithms and software solutions to uncover the relationships between genetic variation and human disease, today announced that Sekar Kathiresan, M.D., a renowned clinical cardiologist and human geneticist, has joined Genomics plc's newly-formed Scientific Advisory Board (SAB) as chair, with immediate effect.

Dr Kathiresan is one of the world leaders in the genetics of heart disease. He is the director of preventive cardiology at Massachusetts General Hospital, an associate member in the Broad Institute's Program in Medical and Population Genetics, and an associate professor of medicine at Harvard Medical School. He received his B.A. in history and graduated summa cum laude from the University of Pennsylvania in 1992. He received his M.D. from Harvard Medical School in 1997. Sekar completed his clinical training in internal medicine and cardiology at MGH and served as Chief Resident in Internal Medicine at MGH in 2002-2003. He pursued research training in cardiovascular genetics through a combined experience at the Framingham Heart Study and the Broad Institute of MIT and Harvard. In 2008, he joined the research faculties of the MGH Cardiovascular Research Center and the MGH Center for Human Genetic Research. In 2015 Sekar was selected by the National Institutes of Health to join a panel of experts formed to steer President Obama's Precision Medicine Initiative.

Sekar Kathiresan, M.D., said: "Genomics plc is dedicated, as am I, to making sense of the explosion in genomic data to improve patient care. The Company has developed a unique analytical platform for genomic data analysis and interpretation, and I am excited to be joining the Genomics SAB. I look forward to working with the team to help guide the next stage in the Company's development."

John Colenutt, CEO at Genomics plc, said: "I would like to welcome Sek to Genomics plc. We have established the SAB to support the Company in achieving its ambitions as a leading analysis company in the genomics space. We are delighted to be working with such a highly-regarded and world-renowned human geneticist. I am confident that Sek's experience and knowledge will prove a tremendous asset as Genomics plc gains momentum and continues to grow – his appointment as Chair demonstrates our commitment to being a global leader in the field of genomics."

For further information please contact:

Zyme Communications
Lorna Cuddon
Tel: +44 (0)7811996942

About Genomics plc

Genomics was founded by four leading Oxford academics, including Professor Peter Donnelly, Director of The Wellcome Trust Centre for Human Genetics, and Professor Gil McVean, Director of The Big Data Institute. The Company has developed a unique platform for genomic sequence data analysis and interpretation which combines world-leading expertise in statistical analysis and data mining with a unique integrated database linking genotypes and phenotypes. Genomics England, the company running the UK project to undertake whole genome sequencing of 100,000 patients in the National Health Service, has appointed Genomics plc as a Platform Partner and has also awarded the Company three SBRI grants. Genomics plc is also working with four major pharmaceutical companies to bring the benefits of genomic analysis to their drug development processes. The Company is supported by major investors, including IP Group, Invesco Perpetual, Woodford Investment Management and Lansdowne Partners.